Technical Analysis for SNPX - Synaptogenix, Inc.

Grade Last Price % Change Price Change
F 2.96 -0.67% -0.02
SNPX closed down 0.67 percent on Friday, November 1, 2024, on 12 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
MACD Bearish Signal Line Cross Bearish -0.67%
Doji - Bullish? Reversal -0.67%
Down 3 Days in a Row Weakness -0.67%
Gapped Down Weakness -0.67%
Fell Below 20 DMA Bearish -3.74%
MACD Bearish Centerline Cross Bearish -3.74%

   Recent Intraday Alerts

Alert Time
Up 1% about 22 hours ago
Down 3% 2 days ago
Fell Below Previous Day's Low 2 days ago
Down 2 % 2 days ago
Down 1% 2 days ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Synaptogenix, Inc. Description

Synaptogenix is a clinical-stage biopharmaceutical company that has historically worked to develop novel therapies for neurodegenerative diseases. Synaptogenix has conducted clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's disease. Preclinical studies have also demonstrated Bryostatin's regenerative mechanisms of action for the rare disease, Fragile X syndrome, and for other neurodegenerative disorders such as multiple sclerosis, stroke, and traumatic brain injury. The U.S. Food and Drug Administration has granted Orphan Drug Designation to Synaptogenix for Bryostatin-1 as a treatment for Fragile X syndrome. Bryostatin-1 has already undergone testing in more than 1,500 people in cancer studies, thus creating a large safety data base that will further inform clinical trial designs.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Biology Neuroscience Rare Diseases Alzheimer's Disease Multiple Sclerosis Neurodegenerative Diseases Stroke Amyotrophic Lateral Sclerosis Neurodegeneration Neurodegenerative Disorders Fragile X Syndrome Traumatic Brain Injury

Is SNPX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 8.775
52 Week Low 2.72
Average Volume 32,286
200-Day Moving Average 4.19
50-Day Moving Average 3.22
20-Day Moving Average 3.10
10-Day Moving Average 3.19
Average True Range 0.22
RSI (14) 43.82
ADX 20.86
+DI 21.34
-DI 16.07
Chandelier Exit (Long, 3 ATRs) 3.05
Chandelier Exit (Short, 3 ATRs) 3.41
Upper Bollinger Bands 3.49
Lower Bollinger Band 2.72
Percent B (%b) 0.31
BandWidth 24.88
MACD Line -0.03
MACD Signal Line -0.02
MACD Histogram -0.0124
Fundamentals Value
Market Cap 60.36 Million
Num Shares 20.4 Million
EPS -0.85
Price-to-Earnings (P/E) Ratio -3.48
Price-to-Sales 0.00
Price-to-Book 0.15
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.08
Resistance 3 (R3) 3.09 3.06 3.06
Resistance 2 (R2) 3.06 3.03 3.06 3.05
Resistance 1 (R1) 3.01 3.02 3.00 3.00 3.04
Pivot Point 2.99 2.99 2.98 2.98 2.99
Support 1 (S1) 2.93 2.96 2.92 2.92 2.88
Support 2 (S2) 2.91 2.94 2.90 2.87
Support 3 (S3) 2.86 2.91 2.86
Support 4 (S4) 2.84